Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (51-60 of 161) with videos related to

Pageof 17
Sort By:
Pragmatic and Observational Research|June 13, 2017
Reduced adherence to antiretroviral therapy is associated with residual low-level viremiaFranco Maggiolo, Elisa Di Filippo, Laura Comi, et al.
BMC Infectious Diseases|June 27, 2018
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015Eugenia Quiros-Roldan, Paola Magro, Elena Raffetti, et al.
Journal of the International AIDS Society|November 15, 2014
Early clinical response and presence of viral resistant minority variants: a proof of concept studyAnnapaola Callegaro, Elisa Di Filippo, Noemi Astuti, et al.
Journal of the International AIDS Society|November 14, 2014
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practiceSilvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, et al.
Patient Related Outcome Measures|March 4, 2015
Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observationFranco Maggiolo, Giorgio L Colombo, Sergio Di Matteo, et al.
Diseases (Basel, Switzerland)|March 27, 2026
Healthcare Resource Consumption and Related Costs of People Living with HIV and Antiviral Treatment: A Retrospective Observational Study in ItalyLuca Degli Esposti, Stefania Mazzoni, Maria Cappuccilli, et al.
Antiviral Therapy|April 29, 2022
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trialFranco Maggiolo, Nicola Gianotti, Laura Comi, et al.
Current HIV Research|May 17, 2007
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAARTRenato Maserati, Andrea Foli, Lina Tomasoni, et al.
Antiviral Therapy|February 17, 2007
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimensFranco Maggiolo, Diego Ripamonti, Carlo Torti, et al.
Plos Pathogens|May 30, 2009
Increasing clinical virulence in two decades of the Italian HIV epidemicViktor Müller, Franco Maggiolo, Fredy Suter, et al.
Pageof 17

Showing results (51-60 of 161) with videos related to

Sort By:
Pageof 17
Pragmatic and Observational Research|June 13, 2017
Reduced adherence to antiretroviral therapy is associated with residual low-level viremiaFranco Maggiolo, Elisa Di Filippo, Laura Comi, et al.
BMC Infectious Diseases|June 27, 2018
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015Eugenia Quiros-Roldan, Paola Magro, Elena Raffetti, et al.
Journal of the International AIDS Society|November 15, 2014
Early clinical response and presence of viral resistant minority variants: a proof of concept studyAnnapaola Callegaro, Elisa Di Filippo, Noemi Astuti, et al.
Journal of the International AIDS Society|November 14, 2014
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practiceSilvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, et al.
Patient Related Outcome Measures|March 4, 2015
Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observationFranco Maggiolo, Giorgio L Colombo, Sergio Di Matteo, et al.
Diseases (Basel, Switzerland)|March 27, 2026
Healthcare Resource Consumption and Related Costs of People Living with HIV and Antiviral Treatment: A Retrospective Observational Study in ItalyLuca Degli Esposti, Stefania Mazzoni, Maria Cappuccilli, et al.
Antiviral Therapy|April 29, 2022
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trialFranco Maggiolo, Nicola Gianotti, Laura Comi, et al.
Current HIV Research|May 17, 2007
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAARTRenato Maserati, Andrea Foli, Lina Tomasoni, et al.
Antiviral Therapy|February 17, 2007
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimensFranco Maggiolo, Diego Ripamonti, Carlo Torti, et al.
Plos Pathogens|May 30, 2009
Increasing clinical virulence in two decades of the Italian HIV epidemicViktor Müller, Franco Maggiolo, Fredy Suter, et al.
Pageof 17